Massive hepatocellular carcinoma in dogs: 48 cases (1992–2002)
Authors:
- Julius M. LiptakJLJulius M. Liptak
- William S. DernellWDWilliam S. Dernell
- Eric MonnetEMEric Monnet
- Barbara E. PowersBPBarbara E. Powers
- Annette M. BachandABAnnette M. Bachand
- Juanita G. KenneyJKJuanita G. Kenney
- Stephen J. WithrowSWStephen J. Withrow
- 15 October 2004
- journal article
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 225 (8) , 1225-1230
Abstract
Objective—To determine clinical signs, diagnostic findings, outcome, and prognostic factors in dogs treated surgically for massive hepatocellular carcinoma (HCC) and compare survival times of surgically and conservatively treated dogs. Design—Retrospective study. Animals—48 dogs. Procedure—Medical records were examined for clinical signs, diagnostic and surgical findings, and postoperative outcome. Dogs were allocated into surgery and nonsurgery groups depending on whether curative- intent liver lobectomy was performed. Data from the surgical and nonsurgical groups were analyzed to identify prognostic factors and determine and compare rates of tumor control and survival time. Results—42 dogs were treated surgically, and 6 were managed conservatively. In the surgery group, intraoperative mortality rate was 4.8% with no local recurrence, metastatic rate was 4.8%, and median survival time was > 1,460 days (range, 1 to 1,460 days). High alanine aminotransferase and aspartate aminotransferase activities were associated with poor prognosis. Median survival time for the nonsurgery group was 270 days (range, 0 to 415 days), which was significantly less than that of surgically treated dogs. Conclusions and Clinical Relevance—Liver lobectomy is recommended for dogs with massive HCC because tumor-related mortality rate was 15.4 times higher in dogs in the nonsurgery group, compared with the surgery group. Tumor control was excellent after surgical resection with no local recurrence and a low metastatic rate. Prognostic factors were identified, but their clinical relevance was uncertain because only 9.5% of dogs in the surgery group died as a result of their disease. (J Am Vet Med Assoc 2004;225:1225–1230)Keywords
This publication has 18 references indexed in Scilit:
- Poor Prognosis Associated With Thrombocytosis in Patients With Gastric CancerAnnals of Surgical Oncology, 2002
- The epidemiology and prevention of hepatocellular carcinomaSeminars in Oncology, 2001
- Thrombocytosis as a Prognostic Factor in Endometrial CarcinomaGynecologic Oncology, 1998
- Congenital Interruption of the Portal Vein and Caudal Vena Cava in Dogs: Six Case Reports and a Review of the LiteratureVeterinary Surgery, 1998
- Significance of thrombocytosis in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1994
- Detection of mammalian and avian hepadnaviruses by the polymerase chain reactionVeterinary Microbiology, 1992
- Poor prognosis associated with thrombocytosis in patients with cervical cancerCancer, 1992
- Hepatic NeoplasiaVeterinary Clinics of North America: Small Animal Practice, 1985
- Canine Hepatocellular CarcinomaVeterinary Pathology, 1981
- Canine Hepatic Neoplasms: A Clinicopathologic StudyVeterinary Pathology, 1980